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doxorubicin in this combination regimen compared to doxo-
rubicin administered as a single agent, possibly due to PK 
drug interactions. Out of 18 patients evaluable for a treat-
ment response, two had partial responses (Pr) (breast can-
cer and hepatocellular carcinoma) and six had stable disease 
(SD). Two patients remained on treatment for more than 
1 year. The combination of PlD and T is tolerable, and the 
treatment resulted in clinical benefit. The combination regi-
men should be further explored in appropriate tumor types.
Keywords Pegylated liposomal doxorubicin · 
Temsirolimus · Phase I study · refractory malignancies
Introduction
The mammalian target of rapamycin (mTOr) acts down-
stream of the phosphatidyl-inositol 3 kinase (PI3K)/akt 
pathway and plays a key role in the signaling of malignant 
cell proliferation, differentiation, migration, and survival 
Abstract This study aimed to determine the maximum-
tolerated dose and dose-limiting toxicities of pegylated lipo-
somal doxorubicin (PlD) in combination with temsirolimus 
(T) in patients with refractory solid tumors. Using a standard 
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three dosing cohorts in this phase I study. The starting dose 
level was PlD at 30 mg/m2 every 4 weeks and T at 20 mg 
weekly. Pharmacokinetics (PK) of doxorubicin were evalu-
ated for patients in the expansion cohort. The most common 
treatment-related adverse events of all grades were mucosi-
tis/stomatitis (69.6 %), anorexia (52.2 %), thrombocytope-
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and 25 mg T. PK analyses suggested increased exposure of 
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[1]. Given that an overactive PI3K pathway is frequently 
implicated in the development and progression of a variety 
of malignancies, therapeutic targeting of crucial mediators 
along the PI3K signaling axis, such as mTOr, is an attrac-
tive strategy for cancer therapy.
Temsirolimus (T) (CCI-779, Torisel® Pfizer Inc.) is a sol-
uble ester analog of sirolimus and exerts its antitumor effect 
by selectively inhibiting mTOr. Temsirolimus received 
approval from the Food and Drug administration (FDa) 
for treating patients with advanced renal cell carcinoma, 
based on a pivotal Phase 3 study demonstrating that patients 
receiving T had superior median overall survival when com-
pared to those receiving interferon alpha alone or a com-
bination of the two therapies (10.9, 7.3, and 8.4 months, 
respectively, p = 0.008) [2]. In addition, fewer patients in 
the T group experienced serious adverse events than the 
other two groups [2]. a second mTOr inhibitor everoli-
mus (raD-001, afinitor® norvartis Pharmaceuticals Co.) 
has also been approved for advanced renal cell carcinoma 
after sunitinib or sorafenib treatment failure and for progres-
sive neuroendocrine tumors of pancreatic origin. Therefore, 
mTOr inhibition is a proven antitumor strategy and is being 
evaluated in clinical trials for other cancer indications.
Doxorubicin is a cytotoxic anthracycline antibiotic iso-
lated from Streptomyces peucetius var. caesius, and exerts 
its antitumor effect via inhibition of topoisomerase II [3]. In 
comparison with conventional or liposomal doxorubicin for-
mulations, the pegylated liposomal doxorubicin (PlD) has 
extended blood circulation time, improved tumor localization, 
and better tolerance than conventional formulations [4]. Since 
its FDa approval, PlD is prescribed for refractory metastatic 
ovarian cancer and aIDS-related Kaposi Sarcoma [5, 6].
Several reports have indicated that mTOr inhibition 
may enhance the antitumor effects of cytotoxic agents in 
an additive or synergistic manner when tested in vitro and 
in vivo models of multiple types of human cancers [7, 8]. 
In particular, one preclinical study suggested that mTOr 
inhibition can reverse doxorubicin resistance conferred by 
PTen mutation/akt activation [9].
Based on the evidence suggesting potential synergy 
between mTOr inhibition and doxorubicin, we conducted 
a phase I clinical study evaluating the combination of PlD 
and T in patients with refractory solid malignancies. Here, 
we report the results on the safety, tolerability, pharmacoki-
netics (PK), and efficacy of this combination regimen.
Methods
Study design
This phase I study was an open-labeled, dose escalation 
study of PlD and T in patients with refractory tumors. The 
starting dose level (cohort 1) for the study was 30 mg/m2 
PlD every 4 weeks and 20 mg T weekly (Table 1). a single 
treatment cycle was defined as 4 weeks, and dose-limiting 
toxicities (DlTs) were defined during the first cycle only. 
If none out of three patients in a cohort experienced DlT, 
then three patients proceeded to the next dose level. If two 
or more patients experienced DlT, then dose escalation 
was stopped. If one patient developed DlT, then three more 
patients entered the same dose level. The maximally toler-
ated dose (MTD) was defined as one dose level immedi-
ately below the dose level at which two patients of a cohort 
(of 2–6 patients) experienced DlT during the first cycle. 
Baseline imaging was performed within 28 days prior to 
starting the study and repeated after every two treatment 
cycles. Tumor response was assessed by the response 
evaluation Criteria in Solid Tumors (reCIST) 1.0 guide-
lines. all responses were confirmed by repeat imaging in 
4 weeks. Toxicities were graded according to national 
Cancer institute Common Terminology Criteria for adverse 
events (nCI CTCae), version 3.0. Hematological DlTs 
were defined as grade 4 neutropenia of ≥7 days duration, 
febrile neutropenia of any duration with temperature above 
38.5 °C, grade 4 anemia, or grade 4 thrombocytopenia 
which required transfusion therapy on more than two occa-
sions in 7 days. non-hematological DlTs were defined as 
Grade 3 or 4 toxicity with the specific exceptions of nau-
sea, vomiting, or anorexia. Grade 3 triglycerides were only 
considered a DlT after the administration of appropriate 
lipid-lowering agents. a delay of treatment for ≥14 days 
(consecutive or cumulative) prior to beginning cycle 2 was 
considered a DlT.
Patient population
Patients were eligible to participate if they had a histologi-
cal or cytological diagnosis of a malignant solid tumor that 
had progressed on standard therapies. eligibility criteria 
included the following: life expectancy of at least 8 weeks; 
eastern Cooperative Oncology Group (eCOG) perfor-
mance status (PS) ≤2; age ≥18 years; measurable or evalu-
able disease as defined by reCIST; adequate bone marrow 
function [absolute neutrophil count (anC) ≥1,500/mm3, 
hemoglobin ≥9 g/dl, and platelet count ≥100,000/mm3], 
Table 1  Dose escalation schema
#
 Includes an expansion cohort
Dose  
levels
Pegylated liposomal doxorubicin  
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adequate renal function (serum creatinine ≤2.0 mg/dl or 
creatinine clearance ≥60 ml/min/1.732); adequate hepatic 
function [aspartate aminotransferase (aST), alanine ami-
notransferase (alT) level, alkaline phosphatase ≤2.5× 
institutional upper limit of normal (Uln), and total 
bilirubin level ≤1.5 × Uln]; fasting cholesterol level 
≤350 mg/dl; fasting triglyceride ≤400 mg/dl; albumin 
<3 mg/dl; and no active central nervous system (CnS) 
metastases, and normal left ventricular ejection fraction 
(lVeF ≥ 50 %) by multigated acquisition scan (MUGa). 
Patients may not have had chemotherapy or radiotherapy 
within 4 weeks of starting the protocol treatment. Patients 
must have provided signed and dated informed consent 
forms approved by the Washington University Human 
research Protection Office (HrPO). all patients who 
received at least one treatment were included in the safety 
analysis. The study was conducted under the auspices of 
the Siteman Cancer Center Quality assurance and Safety 
Monitoring Committee.
Treatment administration and dose escalation procedure
Patients received PlD intravenously once every 4 weeks 
and T by intravenous infusion weekly. no treatment cycle 
was started until anC ≥1,500/mm3, the platelets count 
≥100,000/mm3, hemoglobin ≥9.0 g/dl, and all other treat-
ment-related toxicities were grade ≤1. If, after the appro-
priate dose reductions, a treatment-related toxicity required 
a delay of ≥14 days before starting subsequent cycles, the 
patient was taken off study. If any grade ≥2 neutropenia or 
thrombocytopenia occurred at the start of a cycle, admin-
istration of both PlD and T was delayed (no more than 
14 days) until the toxicity resolved to grade 1 or less. For 
patients experiencing toxicities, in subsequent cycles, PlD 
was given at a lower dose level while T could be resumed 
at the prior dose level or a reduced dose level at the discre-
tion of the treating physician. For any occurrences of neu-
tropenic fever, administration of either both drugs (at the 
start of a cycle) or T (during a cycle) was delayed until it 
resolved to grade ≤1 and then both drugs were reduced by 
one dose level. Once the dose was reduced for a subject, 
all subsequent cycles for PlD were administered at the 
reduced dose.
If grade ≥2 stomatitis/mucositis persisted at the start 
of a cycle, administration of both drugs was delayed until 
the toxicity resolved to grade ≤1, and the drug deemed 
responsible for the stomatitis/mucositis was reduced by one 
dose level in the current and subsequent cycles. If neither 
drug was identified as being responsible for the adverse 
events, then both drugs were reduced by one dose level. If 
grade ≥2 stomatitis/mucositis occurred during the weeks 
2–4 of a cycle, T was omitted from the regimen until the 
stomatitis/mucositis resolved to grade ≤1; then, the drug 
deemed responsible for the adverse event was reduced in 
the current and subsequent cycles.
Pharmacokinetic (PK) analyses
The PK of doxorubicin were assessed by analyzing the con-
centrations of doxorubicin in plasma samples collected at 0 
(pre-dose), 0.5, 1.5, and 5 h after the start of drug infusion 
and approximately 48, 96, and 168 h post-infusion. Plasma 
concentrations of doxorubicin were analyzed using a liq-
uid chromatography mass spectrometry analytical method 
(detailed description of bioanalytical methods provided in 
supplementary materials). The PK parameters were esti-
mated using non-compartmental methods. The area under 
the concentration–time curve from time 0 to the last sam-
pling point (aUClast) was calculated using the linear trap-
ezoidal method. The remaining area under the curve from 
the last time point to infinity was calculated using the equa-
tion aUClast−∞ = Clast/kel, where Clast is the last-measured 
plasma concentration and kel is the slope of the concentra-
tion versus time plot during the log-linear terminal phase. 
Total clearance (Cl) and elimination half-life (t1/2) were 
calculated as follows: Cl = dose/aUC, t1/2 = 0.693/kel.
Statistical methods
The primary outcome of this study was assessment of 
toxicity. The results are summarized by simple descrip-
tive summary statistics. The PK variables for doxorubicin 
obtained using non-compartmental methods are summa-
rized using mean ± standard deviations.
Results
Patient characteristics
From april 2008 to June 2011, a total of 23 patients were 
enrolled and treated with PlD and T. Demographic infor-
mation for the study participants is shown in Table 2. The 
median age of patients was 60 years (range 34–80 years). 
The majority of the patients were Caucasian (21 of 23), and 
14 (60.9 %) patients were male. The distribution of eCOG 
PS of 0 and 1 was 21.7 and 65.2 %, respectively. Twenty-
one (91.3 %) patients had received at least one line of prior 
chemotherapy for their cancer. The most common cancer 
diagnoses were colorectal cancer (30.4 %) and breast can-
cer (17.4 %).
Safety and toxicity
The treatment toxicities experienced during the first cycle 
of treatment are summarized in Table 3. Six patients were 
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treated in dose level 1 cohort (PlD 30 mg/m2 and T 20 mg); 
however, one patient never received treatment as she was 
determined to be ineligible after enrollment. Of the remain-
ing five patients, no DlTs were observed (Table 4). Interim 
analysis was performed on this cohort. although there were 
no DlTs at this dose level, the majority of patients were 
unable to complete two full cycles of treatment for evalu-
ation of response, so the decision was made to reduce the 
starting dose level of PlD from 30–25 mg/m2.
Six patients were enrolled in the dose level 1a cohort 
(PlD 25 mg/m2 and T 20 mg), and one patient experienced 
the following DlTs [elevated aST (SGOT), hyperglyce-
mia, and dyspnea]. Dose escalation proceeded as per the 
study protocol to dose level 2a. Six patients were enrolled 
in cohort 2a (PlD 25 mg/m2 and T 25 mg). One patient 
did not receive any treatment. among five treated patients 
in this cohort, none experienced DlTs; therefore, this dose 
level was expanded. Seven patients were enrolled in the 
expansion cohort, for a total of 12 patients treated at this 
dose level. adverse events in each cohort are summarized 
in Table 3. The common treatment-related adverse events 
during cycle 1 were: mucositis/stomatitis (16/23, 69.6 %), 
anorexia (12/23, 52.2 %), platelets (12/23, 52.2 %), and 
fatigue (11/23, 47.8 %).
The reasons patients discontinued treatment in this study 
are summarized in Table 4. Fifteen patients (65.2 %) were 
taken off the study due to disease progression. Two patients 
were removed from the study based on the investigator/
patient’s decisions. One patient in cohort 2a developed 
recurrent mucositis, and the subject was taken off the study 
because no further dose reduction for T was permissible.
Pharmacokinetics
PK analyses of doxorubicin were performed following 
the intravenous infusion of PlD at 25 mg/m2 on day 1 of 
cycle 2 in 6 out of 7 patients in the expansion cohort of 
2a (Fig. 1; Table 5). One patient in the expansion cohort 
did not have blood collected for PK on day 1 of cycle 2 
due to disease progression. The plasma concentrations of 
doxorubicin were well above the lower quantitation limit at 
all time points. although the PK blood sampling schedule 
was limited, it was possible to obtain reliable estimates of 
the terminal t1/2 from the regression analyses of the termi-
nal log-linear decline (Fig. 1). Since the PK analyses were 
performed only on day 1 of cycle 2, it was not possible to 
assess the potential impact of the co-administered T on 
the PK of doxorubicin within our study. Thus, the results 
were compared to those available from the literature; in a 
previous study with the same 25 mg/m2 dose of PlD, the 
average terminal t1/2, aUC0−∞, and Cl values were 45.2 h 
(range 20.8–59.1), 609 µg*h/ml (range 227–887), and 
80 ml/h (range 50–210), respectively [10]. The compari-
son of PK parameters obtained from our current study and 
similar studies in the literature is summarized in Table 5 
[10, 11]. The results suggest that the systemic exposure of 
doxorubicin is much greater in patients receiving the com-
bination therapy than in patients receiving PlD alone.
efficacy
Of 23 patients enrolled in the study, 18 were determined to 
be evaluable for treatment response because they had com-
pleted at least one cycle of treatment and one post-baseline 
imaging assessment. Five patients were not evaluable for 
treatment response due to the following reasons; no post-
baseline imaging study (n = 2), consent withdrawal for 
grade 2 stomatitis (n = 1), discontinuation due to recurrent 
grade 2 stomatitis (n = 1), and discontinuation due to no 
further dose reduction available for PlD (n = 1). Figure 2 
shows a waterfall plot of the treatment effect. Two (11.1 %) 
patients showed Pr and six (33.3 %) patients displayed SD 
Table 2  Baseline clinical and demographic characteristics of 
enrolled patients
#
 One patient each for prostate, gallbladder, esophageal, parotid 
gland, adrenal gland, squamous cell carcinoma of the skin, and 
malignant solitary fibrous tumor
Characteristic Patients (n = 23)
no. %
Gender
 Male 14 60.9





 Caucasian 21 91.3
 african americans 2 8.7
eCOG performance status
 0 5 21.7
 1 15 65.2
 2 3 13.1




 no 7 30.4
 Yes 16 69.6
Primary tumor type
 Colorectal 7 30.4
 Breast 4 17.4
 non-small cell lung 3 13.1
 Hepatocellular 2 8.7
 Others# 7 30.4
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by reCIST. Several patients with less than 20 % increase 
in the maximum changes from the baseline were deemed 
to have progressive disease due to the appearance of one 
or more new lesions. One patient with a Pr (dose cohort 
2a) was on treatment for 6 months, and she was taken off 
study because there was no further dose reduction of T 
allowed for her recurrent stomatitis. This patient had breast 
cancer, and she had received three lines of chemotherapy 
before starting on this trial. The second patient with a Pr 
(dose cohort 1) had hepatocellular cancer (HCC), and she 
was treated for 15 months and then removed for disease 
progression.
among the seven patients with SD, the tumor types 
included HCC (n = 1), non-small cell lung cancer (n = 2), 
colorectal cancer (n = 2), squamous cell carcinoma of the 
skin (n = 1), and malignant solitary fibrous tumor (n = 1). 
The median treatment duration was 4 months (range 
2–12 months). a patient with squamous cell carcinoma of 
the skin received a total of 12 cycles of treatment and had 
received 3 lines of chemotherapy prior to enrolling in the trial.
Discussion
In this phase I study, we assessed the safety and tolerability 
of the combination of PlD and T in patients with refrac-
tory solid tumors. Based on our study, PlD at 25 mg/m2 
every 4 weeks and T at 25 mg weekly appeared to be tol-
erable for patients with refractory solid tumors and is the 
recommended Phase II dose. The observed DlTs were 
elevated aST (SGOT), hyperglycemia, and dyspnea, and 
the most common adverse event of this combination drug 
regimen was mucositis/stomatitis, which was observed in 
16 (69.6 %) patients but at grade ≤2 (Table 3).
Table 3  Summary of common 
drug-related adverse events 




Grade of adverse event Dose level
1 (n = 5) 1a (n = 6) 2a (n = 12)
Grade Grade Grade
1 2 3 4 1 2 3 4 1 2 3 4
Mucositis/stomatitis 3 1 2 7 3
anorexia 2 2 2 1 2 3
Platelets 1 4 6 1
Fatigue 1 2 3 4 1
leukocytes 1 1 3 4
nausea 1 2 1 4 1
Hemoglobin 2 1 1 3 1
lymphocyte 1 1 2 1 1 3
albumin 2 2 2
aST (SGOT) 1 1 1# 2 1
Pain: headache 2 2 1 1
alT (SGTP) 2 2 1
Dyspnea 1 1# 1 1 1
Heartburn/dyspepsia 1 1 1 2
rash/desquamation 2 1 1 1
Glucose (serum) 2# 1 1
neutrophils 1 1 2
Triglyceride (serum) 1 1 2
Pruritus 3 1
Table 4  Summary of reasons 




reasons for treatment cessation 1 (n = 5) 1a (n = 6) 2a (n = 12) Total (n = 23)
Disease progression 1 5 9 15
Investigator/patient decision 1 0 1 2
adverse event 1 1# 0 2
Intercurrent illness 1 0 1 2
no further dose reduction allowed on study 1 0 1 2
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a recently reported study independently determined 
that PlD at 30 mg/m2 every 4 weeks and T at 20 mg/m2 
weekly as the MTD in patients with refractory or recurrent 
bone and soft tissue sarcoma [12]. The study enrolled 15 
adult and pediatric patients, and their median age was 39 
(range 9–70), much younger than those who participated 
in our current study (median 60, range 34–80, Table 2). In 
our study, the starting dose level was 30 mg/m2 PlD every 
4 weeks and 20 mg T. However, the majority of patients 
who received this starting dose level could not com-
plete two full cycles of treatment for a true evaluation of 
response, so PlD was reduced to 25 mg/m2 in the subse-
quent cohorts. Based on the recommended T single agent 
dose of 25 mg weekly, we further explored the combina-
tion of PlD at 25 mg/m2 and T at 25 mg weekly, which 
we determined to be the phase II dose for this combination 
regimen. Of note, our current study used the typical fixed 
mg dose of T approved by the FDa rather than mg/m2 
used in the recent sarcoma study which probably required 
dose adjustment for the pediatric population enrolled [12]. 
Therefore, we believe that the phase II dose for the com-
bination regimen from our study (PlD at 25 mg/m2 every 
4 weeks and T at 25 mg weekly) may be more applicable to 
a general patient population with solid tumors.
The results from our PK analyses for doxorubicin also 
appear to be in line with the findings reported in the recent 
report in sarcoma patients [12]. Our results indicate that 
the weekly administration of T may have an impact on the 
PK profiles of doxorubicin when compared to the reported 
PK variables in the literature (Table 5). Our current study 
involved the PK assessment of doxorubicin only, due to 
the limited availability of blood samples from the enrolled 
patients. However, the recent report in sarcoma patients 
demonstrated that the concurrent administration of T and 
PlD resulted in increased systemic exposure (approxi-
mately twofold increase in aUC) of sirolimus, a major 
active metabolite of T [12]. These observed changes in the 
systemic exposure of doxorubicin and sirolimus are consist-
ent with the previous reports that T, sirolimus, and doxoru-
bicin are substrates for CYP3a4 and also for P-glycoprotein 
[13, 14]. Increased systemic exposure of doxorubicin and 
sirolimus when the two drugs were administered concur-
rently compared with single agent alone as well as some 
overlapping toxicities (e.g., mucositis) may have contrib-
uted to the adverse events observed in our study. Further 
investigations are warranted in order to probe the extent of 
the potential drug interactions for this combination regimen.
emerging preclinical evidence suggests that mTOr inhi-
bition can potentiate the antitumor efficacy of conventional 
cytotoxic agents in multiple tumor types in vivo and in vitro 
[7, 8]. Moreover, mTOr inhibition can overcome acquired 
cancer resistance to drugs targeting topoisomersase II [9, 
15]. These preclinical observations may be clinically rel-
evant as we observed clinical benefit in 44.4 % of patients; 
6 stable diseases (SD, 33.3 %) and 2 partial responses (Pr, 
11.1 %) out of eighteen patients evaluable for treatment 
response. The duration of treatment for patients with SD 
was 4 months. Similarly, PlD and T have been combined 
with bevacizumab in another phase I study [16]. Out of 74 
patients with advanced gynecologic and breast malignan-
cies in that study, clinical benefit was achieved in 37.8 % 
of patients; 1 (1.4 %) complete response (Cr), 14 (18.9 %) 
Pr, and 13 (17.6 %) SD. Moreover, when assessed in 
patients with PI3K pathway aberrations (PI3K mutation or 
PTen loss), this combination regimen resulted in clinical 
benefits (Cr + Pr + SD) in 52 % of patients; 9 (36 %) 
Cr/Pr and 4 (16 %) SD [16]. Our current study did not 
involve mutational analyses for PI3K pathway aberrations, 
Fig. 1  Individual plasma concentration versus time profiles of doxo-
rubicin following intravenous administration of PlD (25 mg/m2) on 
the day 1 of cycle 2 in six patients
Table 5  Pharmacokinetic (PK) parameters of doxorubicin in six 
patients after intravenous administration of PlD (25 mg/m2) on day 
1 of cycle 2
These patients also received weekly T (25 mg). The PK parameters 
from a previous study in patients receiving the 25 mg/m2  dose of 
PlD alone are also provided [10, 11]
aUC0−∞ = area under the concentration versus time curve; 
t1/2 = elimination half-life; Cl = Total clearance
PK parameters Median (ranges) Median (ranges) 
[10, 11]
t1/2 (h) 115 (79–165) 45.2 (20.8–59.1)
aUC0−∞ (µg*h/ml) 2,600 (1,800–4,375) 609 (227–887)
Cl (ml/h) 19 (11–26) 80 (50–210)
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but a subsequent study of this regimen enriched with 
patients selected for these molecular/genetic markers may 
be warranted.
In summary, the results from our current study demon-
strated that the combination of PlD and T is tolerable and 
can yield clinical benefit. The combination regimen should 
be further explored in a phase II trial in patients with 
appropriate tumor types (e.g., advanced HCC, a disease 
with very limited therapeutic options). The efficacy of the 
combination regimen and the PK interaction between the 
two drugs warrant further exploration.
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